NASDAQ: LFWD
Lifeward Ltd Stock

$1.56-0.34 (-17.89%)
Updated Jan 13, 2025
LFWD Price
$1.56
Fair Value Price
N/A
Market Cap
$13.74M
52 Week Low
$1.41
52 Week High
$7.84
P/E
-0.71x
P/B
0.41x
P/S
1.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.00M
Earnings
-$19.30M
Gross Margin
35.3%
Operating Margin
-73.17%
Profit Margin
-77.2%
Debt to Equity
0.35
Operating Cash Flow
-$22M
Beta
0.74
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A

LFWD Overview

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LFWD's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Value
C
Growth
D
Momentum
C
Sentiment
D
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
D
LFWD
Ranked
#113 of 127

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$30.47A
$47.32A
$9.16A
View Top Medical Device Stocks

Be the first to know about important LFWD news, forecast changes, insider trades & much more!

LFWD News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LFWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LFWD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LFWD is good value based on its book value relative to its share price (0.41x), compared to the US Medical Devices industry average (4x)
P/B vs Industry Valuation
LFWD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LFWD due diligence checks available for Premium users.

Valuation

LFWD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.71x
Industry
36.97x
Market
29.88x

LFWD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.41x
Industry
4x
LFWD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LFWD's financial health

Profit margin

Revenue
$6.1M
Net Income
-$3.1M
Profit Margin
-50.3%
LFWD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LFWD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$45.8M
Liabilities
$11.9M
Debt to equity
0.35
LFWD's short-term assets ($25.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFWD's short-term assets ($25.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LFWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.5M
Investing
$0.0
Financing
$0.0
LFWD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LFWD vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LFWDD$13.74M-17.68%-0.71x0.41x
ADGMC$12.94M-6.61%-0.01x0.17x
SSKNC$12.30M0.00%-1.11x1.32x
QTI$10.45M+5.27%-1.37x-1.08x
AEMDD$8.87M-4.80%-0.23x1.47x

Lifeward Stock FAQ

What is Lifeward's quote symbol?

(NASDAQ: LFWD) Lifeward trades on the NASDAQ under the ticker symbol LFWD. Lifeward stock quotes can also be displayed as NASDAQ: LFWD.

If you're new to stock investing, here's how to buy Lifeward stock.

What is the 52 week high and low for Lifeward (NASDAQ: LFWD)?

(NASDAQ: LFWD) Lifeward's 52-week high was $7.84, and its 52-week low was $1.41. It is currently -80.1% from its 52-week high and 10.64% from its 52-week low.

How much is Lifeward stock worth today?

(NASDAQ: LFWD) Lifeward currently has 8,808,143 outstanding shares. With Lifeward stock trading at $1.56 per share, the total value of Lifeward stock (market capitalization) is $13.74M.

Lifeward stock was originally listed at a price of $4,480.00 in Sep 12, 2014. If you had invested in Lifeward stock at $4,480.00, your return over the last 10 years would have been -99.97%, for an annualized return of -54.9% (not including any dividends or dividend reinvestments).

How much is Lifeward's stock price per share?

(NASDAQ: LFWD) Lifeward stock price per share is $1.56 today (as of Jan 13, 2025).

What is Lifeward's Market Cap?

(NASDAQ: LFWD) Lifeward's market cap is $13.74M, as of Jan 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lifeward's market cap is calculated by multiplying LFWD's current stock price of $1.56 by LFWD's total outstanding shares of 8,808,143.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.